From the Journals

Testosterone Replacement Therapy and Prostate Cancer Risk


 

DISCLOSURES:

This study was funded by a consortium of testosterone manufacturers led by AbbVie Inc., with additional financial support from Endo Pharmaceuticals, Acerus Pharmaceuticals Corporation, and Upsher-Smith Laboratories. Bhasin, Lincoff, and Khera reported receiving grants and consulting and personal fees from various sources. The remaining authors disclosed no conflicts of interest.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Continuous glucose monitors for pregnant patients?
MDedge Family Medicine
Premenstrual disorders may be preview of early menopause
MDedge Family Medicine
Trading one’s eggs for a service discount raises tough issues, says ethicist
MDedge Family Medicine
Testosterone treatment helps correct anemia in men with hypogonadism
MDedge Family Medicine
Lack of racial, ethnic diversity in cryopreserved donor sperm in the U.S.
MDedge Family Medicine
AI algorithm aids egg retrieval date during fertility treatment cycles
MDedge Family Medicine
Bipolar disorder may raise risk of polycystic ovarian syndrome
MDedge Family Medicine
What is the link between cellphones and male fertility?
MDedge Family Medicine
Optimal Follow-up After Fertility-Sparing Cervical Cancer Surgery
MDedge Family Medicine
What’s the Disease Burden From Plastic Exposure?
MDedge Family Medicine